C-FBJIsmall molecules, microglia, resilience
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Advance a novel oral TREM2 agonist for Alzheimer's disease, targeting microglial biology to preserve cognition and brain function by enhancing resilience to disease pathology and resolving neuroinflammation.
Oral small-molecule TREM2 agonist in an ongoing Phase 1 clinical trial.
Awarded a $1 million Alzheimer's Association research grant to support the ongoing Phase 1 trial.
Characterize microglial state transitions at the amyloid-beta and tau interface and identify resilience-associated mechanisms with therapeutic relevance in Alzheimer's disease and aging.
Spatial transcriptomics and single-nucleus RNA sequencing of superior frontal cortex samples from octogenarians with or without dementia and cognitively intact centenarians with comparable amyloid-beta accumulation.
Publication of findings that microglial transitions at the amyloid-beta-tau inflection point associate with divergent pathways to dementia and resilience.
The study identified six tissue domains across a spatial pathological continuum of Alzheimer's disease, a transition from early inflammatory to late antigen-presenting microglial phenotypes, and distinct resilience patterns in octogenarians without dementia and centenarians.
Develop Kv1.3 blockers as part of Muna Therapeutics' neurodegeneration pipeline.
Small-molecule Kv1.3 blocker therapeutic program.
Listed in the company pipeline materials.
Discover and validate therapies that slow or stop neurodegenerative diseases including Alzheimer's and Parkinson's by identifying human-relevant mechanisms that preserve brain function and resilience.
All-in-human discovery and validation platform using single-cell spatial multi-omics, bioinformatics, structural biology, computational chemistry, and cell-based screening.
Described as Muna Therapeutics' core discovery and validation approach.